SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today

Passage Bio (PASG) Ticks Up 1.01% to $4.99 as Shares Hold Above Key Support - Gap Up Stocks

Remix to go public in reverse merger with once high-flying Passage Bio

Passage Bio and Remix Therapeutics Announce Merger Agreement

PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff?

Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing

Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?

Sector Update: Health Care Stocks Softer Late Afternoon

Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says

Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

$PASG stock is down 33% today. Here's what we see in our data.

FDA wants a controlled trial even as Passage Bio posts biomarker gains

symbol__ Stock Quote Price and Forecast